← Eichor
Condition: Neuroendocrine Tumor Metastatic Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Neuroendocrine Tumor Metastatic

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Phase 2 · 1 location(s) · Kevin Kim, MD · NCT07237100CapTemY90 for Grade 2/3 NET Liver Metastases
Phase 2 · 4 location(s) · Abramson Cancer Center at Penn Medicine · NCT04339036Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers
NA · 1 location(s) · Institute of Oncology Ljubljana · NCT07407166Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresecta
Phase 2 · 1 location(s) · Philogen S.p.A. · NCT06284590A Study of ST-1898 for Unresectable or Metastatic Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Scitech-Mq Pharmaceuticals Limited · NCT06359860A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Krystal Biotech, Inc. · NCT05970497BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Phase 3 · 30 location(s) · Canadian Cancer Trials Group · NCT02821013Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05155033FMT to Convert Response to Immunotherapy
Phase 1/Phase 2 · 1 location(s) · The Netherlands Cancer Institute · NCT05251389Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Phase 1 · 10 location(s) · Circle Pharma · NCT06577987Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion
Phase 1/Phase 2 · 4 location(s) · Vastra Gotaland Region · NCT03685890A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanom
Phase 1 · 2 location(s) · Yana Najjar · NCT04572451A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Phase 1/Phase 2 · 4 location(s) · OncoResponse, Inc. · NCT06090266NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
Phase 1 · 2 location(s) · Centre Hospitalier Universitaire Vaudois · NCT06889766Evaluation of the CONVIVO System
NA · 1 location(s) · Dartmouth-Hitchcock Medical Center · NCT05139277A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
Phase 2 · 3 location(s) · Abramson Cancer Center at Penn Medicine · NCT03646617IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Phase 1 · 2 location(s) · TuHURA Biosciences, Inc. · NCT06940440Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07627698TARGETed Therapy Drug MONITOring in DIGestive Oncology
NA · 29 location(s) · UNICANCER · NCT05443087Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT03412877Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Can
Phase 2 · 13 location(s) · National Cancer Institute (NCI) · NCT05691465Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and
Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT07016230Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
Phase 2 · 1 location(s) · University of Miami · NCT06627244In Vivo Liquid Biopsy of Melanoma (Cytophone)
NA · 1 location(s) · Cytoastra · NCT06488365Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Phase 1/Phase 2 · 10 location(s) · Obsidian Therapeutics, Inc. · NCT06060613Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
Phase 1 · 2 location(s) · St Vincent's Hospital, Sydney · NCT07203391Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
Phase N/A · 39 location(s) · Grupo Español Multidisciplinar de Melanoma · NCT03605771
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.